Mylan’s generic Precose gets green light from FDA
PITTSBURGH — The Food and Drug Administration has approved a generic diabetes drug made by Mylan, the drug maker said Tuesday.
Mylan announced the approval of acarbose tablets in the 25-mg, 50-mg and 100-mg strengths. The drug is a version of Bayer’s Precose, used with diet and exercise to improve glycemic control in adults with Type 2 diabetes.
The drug had sales of around $23 million during the 12-month period ended in September, according to IMS Health.
Pfizer’s Germano to speak at 2011 Armada Specialty Pharmacy Summit
FLORHAM PARK, N.J. — Pfizer president and general manager for specialty care and oncology, Geno Germano, will deliver the “State of the Pharma/Biotech Industry Address” at the 2011 Armada Specialty Pharmacy Summit, Armada Health Care said Tuesday.
The summit, which will take place in Las Vegas in May, is in its seventh year and is expected to bring 1,500 participants representing 400 specialty healthcare organizations, including specialty pharmacy providers, pharmaceutical and biotech companies, wholesale distributors and others.
Germano joined Pfizer when the company bought out Wyeth, where he was president of the U.S. and pharmaceutical business units. He previously served numerous other positions at Wyeth and also worked at Johnson & Johnson.
Earlier this month, Armada announced that former President George W. Bush would deliver the keynote speech at the summit.
Takeda, Zinfandel form partnership
OSAKA, Japan — Japanese drug maker Takeda Pharmaceutical has signed an agreement with Durham, N.C.-based Zinfandel Pharmaceuticals to develop a test for assessing Alzheimer’s disease risk in adults, the two companies said.
Under the agreement, Zinfandel will receive $9 million upfront plus up to $78 million in milestone payments, plus royalties, for licensing rights to the TOMM40 assay. Zinfandel CEO Allen Roses and researchers at the company recently discovered the TOMM40 biomarker, and the company is developing it to identify people at high risk for developing Alzheimer’s within five years.
The deal includes potential use of the Takeda drug pioglitazone in combination with the assay. Studies have shown the pioglitazone, the active ingredient in the diabetes drug Actos, may slow progression of Alzheimer’s.